FDA warns of eye condition from GLP-1 use
The US Food and Drug Administration (FDA) has warned of a potential association between glucagon-like peptide-1 (GLP-1) receptor agonists and nonarteritic anterior ischemic optic neuropathy (NAION), requiring updated warning labels